Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Intriguing Strange Cruising Objections you Should Visit - 2New movies to watch this weekend: See 'Wake Up Dead Man: A Knives Out Mystery' in theaters, rent 'Bugonia,' stream 'Caught Stealing' on Netflix
- 3Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
- 4Parents who delay baby's first vaccines also likely to skip measles shots
- 56 Shades Brands For Seniors
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 2024's Hot Games: Must-Play Titles of the Year
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Single women risk rape and exploitation in search for better life in Europe
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- 5 Arising Professions in Environmentally friendly power
- Cocoa Prices Undercut Amid the Prospects of Abundant Supplies
